Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
•
Endocrinology
Do you have a preference of denosumab over zoledronic acid in patients with metastatic breast cancer with osseous involvement with normal renal function?
Related Questions
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
How do you treat front line de novo HER2 positive metastatic breast cancer with brain metastases?
Is there benefit of cold-cap use while patient is on sacituzumab-govitecan?
What are your top takeaways in Breast Cancer from ESMO 2024?
How would you approach a patient with metastatic high grade neuroendocrine carcinoma of the breast which is HR+ HER2 negative?
Do you recommend using a ctDNA assay for a patient with HER2+ metastatic breast cancer in a continued CR to guide decision about whether to stop anti therapy?
How, if at all, do you use changes in SUV on a PET-CT to assess for disease progression/response in patients with metastatic breast cancer?
What are your top takeaways in Medical Oncology from SABCS 2024?
What are your top takeaways in Breast Cancer from ASCO 2024?
